Ono Pharmaceutical Co. (OTCMKTS:OPHLF - Get Free Report) shares gapped down before the market opened on Wednesday . The stock had previously closed at $11.21, but opened at $10.06. Ono Pharmaceutical shares last traded at $10.06, with a volume of 274 shares trading hands.
Ono Pharmaceutical Price Performance
The stock has a market capitalization of $5.21 billion, a PE ratio of 15.86 and a beta of 0.49. The company has a quick ratio of 2.56, a current ratio of 3.07 and a debt-to-equity ratio of 0.13. The stock's 50 day moving average price is $10.35 and its 200-day moving average price is $10.57.
Ono Pharmaceutical Company Profile
(
Get Free Report)
Ono Pharmaceutical Co, Ltd., together with its subsidiaries, produces, purchases, and sells pharmaceuticals and diagnostic reagents worldwide. It offers Opdivo Intravenous Infusion and Kyprolis Intravenous Injection for malignant tumors; Emend capsules/Proemend intravenous injections for chemotherapy-induced nausea and vomiting; Demser capsules for the symptoms in patients with pheochromocytoma; and Mektovi, Velexbru, and Braftovi capsules for malignant tumors, as well as ADLUMIZ tablets for cancer cachexia.
Featured Stories
Before you consider Ono Pharmaceutical, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Ono Pharmaceutical wasn't on the list.
While Ono Pharmaceutical currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Unlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.